Torrent Pharmaceuticals Ltd Share Price Today - Torrent Pharmaceuticals Ltd Stock Price Live NSE/BSE

Torrent Pharmaceuticals Ltd

NSE: TORNTPHARM BSE: 500420

₹4380.80

(0.41%)

Mon, 11 May 2026, 05:37 am

MTF 5xInvest in Torrent Pharmaceuticals Ltd with 5x Leverage Buy with MTF

Market Cap1482.45B

PE Ratio65.26

Dividend0.80

Health Technology

Pharmaceuticals: Major

24.5K

Torrent Pharmaceuticals Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
148250.95
Net Profit
1911.25
P/B
14.42
Sector P/E
34.27
P/E
57.28
EV/EBITDA
30.13
Debt/Equity (Industry)
0.26
Interest Cover (Industry)
10.95
ROCE (Industry)
16.47
RONW (Industry)
14.44
ROE
26.46
ROCE
25.84
Debt/Equity
0.50
EPS (TTM)
68.12
Dividend Yield
0.14
Book Value
249.65
Interest Cover
11.59

Analysis

all

Pros

Dividends per share have increased over the past 10 years.
Dividends paid are well covered by earnings (3.6x coverage).
Dividends after 3 years are expected to be well covered by earnings (3x coverage).
Cash flow for Torrent Pharmaceuticals is expected to increase by more than 50% in 2 years time.
Torrent Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 7.2%.

Cons

Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
Torrent Pharmaceuticals's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Torrent Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
Torrent Pharmaceuticals's earnings are expected to grow by 16.6% yearly, however this is not considered high growth (20% yearly).
Torrent Pharmaceuticals's earnings growth is positive but not above the India market average.

Financials

Ratios

Shareholders	MAR 2026	DEC 2025	SEPT 2025	JUN 2025	MAR 2025
Promoters	68.31	68.31	68.31	68.31	68.31
FII	16.18	16.13	15.92	16.09	16.31
DII	9.06	9.14	9.28	8.65	8.35
Public	6.45	6.42	6.49	6.94	7.03
Government	0.00	0.00	0.00	0.00	0.00

Technical Analysis

RSI

69.72

MACD

55.13

50 DMA

4252.71

200 DMA

3868.86

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	5053.53	4591.63	4388.37	4129.73	3926.47	3667.83	3205.93
Fibonacci	4591.63	4415.19	4306.18	4129.73	3953.29	3844.28	3667.83
Camarilla	4312.12	4269.78	4227.44	4129.73	4142.76	4100.42	4058.08

Pivots Level: Classic

+923.80

5053.53

+461.90

4591.63

+258.63

4388.37

4129.73

Pivot Point

LTP: 4492

-203.27

3926.47

-461.90

3667.83

-923.80

3205.93

Moving Average

SMAEMA

Period

Value

10-EMA
4317.23
20-EMA
4259.66
30-EMA
4237.50
50-EMA
4204.03
100-EMA
4098.61
200-EMA
3899.16

Announcement Date	Purpose	Action	Ex Date
27 Mar 2026	egm
13 Feb 2026	dividend	₹29.00 Dividend /Share	19 Feb 2026
13 Feb 2026	board-meetings	Quarterly Results, Interim Dividend
18 Jan 2026	dividend	Interim Dividend - Rs 29 Per Share	19 Feb 2026
07 Nov 2025	board-meetings	Quarterly Results
04 Jul 2025	agm
20 May 2025	dividend	₹6.00 Dividend /Share	20 Jun 2025
24 Jan 2025	dividend	₹26.00 Dividend /Share	01 Feb 2025
01 Jan 2025	dividend	Interim Dividend - Rs. - 26	01 Feb 2025
31 Dec 2024	dividend	Interim Dividend - Rs 26 Per Sh	01 Feb 2025

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Lupin Ltd

Cipla Ltd

Divis Laboratories Ltd

Torrent Pharmaceuticals Ltd About

Torrent Pharmaceuticals is engaged in manufacturing, developing and marketing of generic pharmaceutical formulations.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1972

Headquarters

CEO

Samir Mehta

Employees

Contact

Website

http://www.torrentpharma.com

investorservices@torrentpharma.com

Phone

91-79-26599000

Location

Torrent House, Off Ashram Road, Ahmedabad, Gujarat, 380009

Year	History
2019	Amended AOA/MOA. Signed licensing agreement with Glenmark for co-marketing Remogliflozin Etabonate. Changed Registrar & Share Transfer Agent to KFIN TECHNOLOGIES PRIVATE LIMITED.
2021	USFDA inspection at Levittown manufacturing facility. Introduced molnupiravir as Molnutor®. Entered Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19.
2022	Acquired 100% stake in Curatio Health Care Private Limited. Recommended bonus shares in 1:1 ratio.
2023	Signed licensing agreement with Zydus for co-marketing Saroglitazar Mg. Started construction of Virochannagar manufacturing facility. Received EIR from US FDA for Dahej facility.
2024	Entered into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals for novel GI drug. Commissioned subsidiaries in Colombia and Chile.

Client Name	Order Side	QTY	Avg Price	Date
TORRENT INVESTMENTS PRIVATE LIMITED	Sell	4972020	3104.4	30 Oct 2024
TORRENT INVESTMENTS PRIVATE LIMITED	Sell	4972020	3103.07	30 Oct 2024
INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.	Sell	1149669	2365.32	29 May 2020
BLACKROCK ADVISORS LLC A/C THE MASTER TRUST BANK OF JAPAN L	Buy	2040623	2367.2	29 May 2020
LAVENDER INVESTMENTS LIMITED	Sell	901207	1475.08	15 Jun 2018
MEHTA SAPNA SAMIR	Sell	8858864	1440	29 Mar 2017
TORRENT PRIVATE LIMITED	Buy	8858864	1440	29 Mar 2017
TORRENT PRIVATE LIMITED	Buy	5885276	1401	28 Mar 2017
VARUN SUDHIRBHAI MEHTA	Sell	1749900	1401	28 Mar 2017
TORRENT PRIVATE LIMITED	Buy	19704108	1401	28 Mar 2017

Torrent Pharmaceuticals Ltd News

Torrent Pharma Board Meet on May 22 for FY26 Results

Torrent Pharmaceuticals schedules Board meeting on May 22, 2026 to approve audited FY26 results, consider final dividend, and evaluate fund-raising via QIP and other modes.

09 May 2026

companies

Torrent Pharma NCLT Meeting Approves JB Pharma Merger

Torrent Pharmaceuticals shareholders approve scheme of amalgamation with J. B. Chemicals & Pharmaceuticals Limited at NCLT convened meeting held on April 28, 2026 with requisite majority.

29 Apr 2026

companies

Torrent Pharma Clears USFDA Inspection with Zero Obs

Torrent Pharmaceuticals' Bileshwarpura oncology facility successfully completed USFDA inspection from April 6-10, 2026, with zero observations, demonstrating strong regulatory compliance.

13 Apr 2026

companies

Torrent Pharma Clears USFDA Inspection with Zero Obs

Torrent Pharmaceuticals' Bileshwarpura oncology facility successfully completed USFDA inspection from April 6-10, 2026, with zero observations, demonstrating strong regulatory compliance.

10 Apr 2026

companies

Torrent Power Sells UNM Foundation Stake to Parent

Torrent Power Limited sold 50,000 equity shares of UNM Foundation to its holding company Torrent Investments Limited for ₹5,00,000 on March 30, 2026.

31 Mar 2026

companies

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800